The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series.
The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series.
复制标题
DOI：
--
复制
发表时间：
2001-02
期刊：
影响因子：
11.2
通讯作者：
D. Levine;J. Boyd
中科院分区：
文献类型：
--
作者：
D. Levine;J. Boyd
我们的目的是检测雄激素受体（AR）基因（CAG）n重复多态性变异是否影响卵巢癌生殖系BRCA突变的发生率或卵巢癌诊断年龄。使用病例系列研究设计，对179名连续的德系犹太卵巢癌患者进行了AR重复长度和BRCA突变状态的基因分型。AR重复序列长度与BRCA突变之间没有关联。然而，携带短AR等位基因的两组卵巢癌患者（有或无BRCA突变）的诊断时间比不携带短等位基因的患者平均提前7.2年（95%置信区间，2.3-12.1）（P = 0.004）。这些数据表明，AR等位基因长度影响卵巢癌的诊断年龄，而与BRCA突变状态无关。
Our objectives were to test whether polymorphic variation in the (CAG)n repeat of the androgen receptor (AR) gene affects penetrance of germ-line BRCA mutations for ovarian cancer or age of diagnosis for ovarian cancer. Using a case-series study design, 179 consecutive Ashkenazi Jewish ovarian cancer patients were genotyped for AR repeat length and BRCA mutation status. There was no association between AR repeat length and presence of a BRCA mutation. However, ovarian cancer patients from both groups (with or without BRCA mutation) who carried a short AR allele were diagnosed an average of 7.2 (95% confidence interval, 2.3-12.1) years earlier than patients who did not carry a short allele (P = 0.004). These data suggest that AR allele length affects age of diagnosis of ovarian cancer, irrespective of BRCA mutation status.